In a report released today, Brandon Couillard from Jefferies reiterated a Hold rating on Luminex (NASDAQ: LMNX), with a price target of $27. The company’s shares closed yesterday at $34.72, close to its 52-week high of $35.37.
According to TipRanks.com, Couillard is a top 100 analyst with an average return of 28.4% and a 75.5% success rate. Couillard covers the Healthcare sector, focusing on stocks such as DENTSPLY SIRONA Inc, Organovo Holdings, and Exact Sciences.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Luminex with a $26.50 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $35.37 and a one-year low of $18.62. Currently, Luminex has an average volume of 365.7K.
Based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Luminex Corp. develops, manufactures and markets proprietary biological testing technologies and products with applications throughout the life sciences and diagnostics industries. The company was founded by Mark B. Chandler and Van S. Chandler in May 1995 and is headquartered in Austin, TX.
